Division of Cardiology, Departments of Cardiac Sciences and Community Health Sciences, Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta.
Section of Cardiology, Departments of Pediatrics, Cardiac Sciences, and Biochemistry and Molecular Biology, Libin Cardiovascular Institute, Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta.
J Am Soc Echocardiogr. 2021 May;34(5):503-510. doi: 10.1016/j.echo.2020.12.009. Epub 2020 Dec 24.
Cardiac allograft vasculopathy (CAV) is an important adverse prognostic factor for pediatric heart transplant (HT) recipients. Invasive coronary angiography (ICA) is the gold standard for CAV detection but lacks sensitivity for early microvascular changes and cumulative radiation exposure is of concern. Real-time myocardial contrast echocardiography (RTMCE) using ultrasound enhancing (contrast) agents performed during dobutamine stress echocardiography (DSE) can assess myocardial function, perfusion, and microvascular integrity. The objective of this study was to determine the safety and feasibility of RTMCE during DSE to detect CAV in a pediatric HT population.
HT patients 10-21 years of age were recruited to undergo DSE with RTMCE to determine technical feasibility, test tolerability and adverse event rate, and detection of perfusion defects compared with ICA-detected CAV. Thirty-six patients from two centers were enrolled, with a mean age 13.5 ± 4.3 years; 21 (58%) were male. Wall motion and myocardial perfusion were qualitatively assessed and compared with ICA findings of CAV. Myocardial blood flow (MBF) at rest and peak stress was quantified, and myocardial blood flow reserve (MBFR) was defined as the ratio of peak to rest MBF.
Five (14%) patients had CAV by ICA, two with obstructive disease and three with mild CAV. Real-time myocardial contrast echocardiography was feasible in 32 (89%) patients. Three patients had wall motion defects, including one with a mixed defect and two with fixed defects. A perfusion abnormality was present in five patients, two of whom had obstructive CAV and one with mild CAV. Sensitivity and specificity of RTMCE for CAV detection were 60% and 94%, respectively, and diagnostic accuracy was 89%. MBFR assessment was feasible in 20 (63%) patients. The mean MBFR was 3.4 ± 0.7. Patients with CAV had lower MBFR than those without (2.0 ± 0.2 vs 3.7 ± 0.8; P < .01). There were no serious adverse events related to RTMCE.
Dobutamine stress RTMCE appears to be safe and feasible for the assessment of CAV in pediatric HT recipients. Further assessment is warranted to determine whether this noninvasive technique could provide a reliable alternative to ICA.
心脏同种异体移植血管病(CAV)是儿科心脏移植(HT)受者重要的不良预后因素。有创冠状动脉造影(ICA)是检测 CAV 的金标准,但对早期微血管变化的敏感性不足,且累积辐射暴露令人担忧。实时心肌对比超声心动图(RTMCE)结合超声增强剂(对比剂)在多巴酚丁胺负荷超声心动图(DSE)期间进行,可评估心肌功能、灌注和微血管完整性。本研究旨在确定在儿科 HT 人群中使用 DSE 进行 RTMCE 检测 CAV 的安全性和可行性。
招募年龄在 10-21 岁的 HT 患者进行 DSE 联合 RTMCE,以确定技术可行性、检测的耐受性和不良事件发生率,并与 ICA 检测到的 CAV 进行比较。来自两个中心的 36 名患者被纳入研究,平均年龄 13.5 ± 4.3 岁;21 名(58%)为男性。定性评估节段性室壁运动和心肌灌注,并与 ICA 发现的 CAV 进行比较。静息和峰值负荷时定量测量心肌血流(MBF),定义心肌血流储备(MBFR)为峰值与静息 MBF 的比值。
5 名(14%)患者经 ICA 诊断为 CAV,其中 2 例为梗阻性病变,3 例为轻度 CAV。32 名(89%)患者 RTMCE 可行。3 名患者存在节段性室壁运动异常,其中 1 例为混合性异常,2 例为固定性异常。5 名患者存在灌注异常,其中 2 例为梗阻性 CAV,1 例为轻度 CAV。RTMCE 对 CAV 检测的敏感性和特异性分别为 60%和 94%,诊断准确性为 89%。20 名(63%)患者可进行 MBFR 评估。平均 MBFR 为 3.4 ± 0.7。有 CAV 的患者 MBFR 低于无 CAV 的患者(2.0 ± 0.2 比 3.7 ± 0.8;P <.01)。无与 RTMCE 相关的严重不良事件。
多巴酚丁胺负荷 RTMCE 似乎安全且适用于评估儿科 HT 受者的 CAV。需要进一步评估以确定该非侵入性技术是否可作为 ICA 的可靠替代方法。